Clinical trial

Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

NCT03214003

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

RADIATION · Unmapped registry intervention SIB Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Standard Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-06-30

PhaseNA

Conditions

Small Cell Lung Cancer Limited Stageunresolved

Radiotherapyunresolved

Interventions

SIBRADIATION

StandardRADIATION

Sponsors & collaborators

Anhui Shi, MDlead sponsor

Sun Yat-sen Universitycollaborator

Fudan Universitycollaborator

Xijing Hospitalcollaborator

Henan Cancer Hospitalcollaborator

Jilin Provincial Tumor Hospitalcollaborator

First Affiliated Hospital of Xinjiang Medical Universitycollaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciencescollaborator

Air Force General Hospital of the PLAcollaborator

China-Japan Friendship Hospitalcollaborator

Peking University Third Hospitalcollaborator

Peking Union Medical College Hospitalcollaborator

Beijing Hospitalcollaborator

Beijing Chao Yang Hospitalcollaborator

Peking University People's Hospitalcollaborator

Peking University First Hospitalcollaborator

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03214003 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.